Eirik Joakim Tranvåg
- Phone+47 55 58 61 31+47 918 84 444
- Visitor AddressOverlege Danielsens husÅrstadveien 215009 BergenRoom446
- Postal AddressPostboks 78045020 Bergen
PhD project: priority setting for new and expensive cancer drugs - seeking new roles for age and biomarkers in clinical decision making.
General research interests:
Priority setting in health care
Age and priority setting
Health inequalities, measures of health inequality
- 2018. Clinical decision making in cancer care: a review of current and future roles of patient age. BMC Cancer. 7 pages.
- 2013. Health inequalities in Ethiopia: modeling inequalities in length of life within and between population groups. International Journal for Equity in Health. 8 pages.
- 2019. Organ donation with the use of normothermic regional perfusion in patients who die after cardiac and respiratory arrest after withdrawal of life-sustaining treatment. .
- 2018. Er protonterapi riktig bruk av sparsomme ressurser? Tidsskrift for Den norske legeforening. 1504-1505.
- 2016. E.J. Tranvåg & K.H. Onarheim svarer. Tidsskrift for Den norske legeforening. 204-204.
- 2017. Cancer Biomarkers: Ethics, Economics and Society. Megaloceros Press.
- 2016. Den brutale arven etter Ebola. Aftenposten Viten.
- 2019. Konfidensielle legemiddelpriser undergraver tilliten til systemet. Tidsskrift for Den norske legeforening. 2 pages.
- 2015. Ebola er ikke Sierra Leones største problem. Tidsskrift for Den norske legeforening.
Tranvåg EJ, Norheim OF, Ottersen T. Clinical decision making in cancer care: a review of current and future roles of patient age. BMC Cancer. 2018 Dec 1;18(1):546.
Tranvåg EJ, Norheim OF. How can biomarkers influence priority setting for cancer drugs? Chapter in Cancer biomarkers: ethics, economics and society. Eds. Blanchard A & Strand R. Megaloceros press 2017.
Tranvåg EJ, Onarheim KH. Ebola er ikke Sierra Leones største problem. Tidsskriftet for den Norske Legeforening 2015; 135:2192 – 3
Tranvåg EJ, Nygaard E, Norheim OF. Hvordan påvirker prioriteringsvilkårene rettighetstildelingen i Helsedirektoratets prioriteringsveiledere? Michael 2015; 12: 416–27.
Tranvåg EJ, Ali M, Norheim OF. Health inequalities in Ethiopia: modeling inequalities in length of life within and between population groups. Int J Equity Health. 2013;12:52
Opinion pieces (in norwegian)
E-helse er ikke svaret, debattinnlegg i Dagens Medisin 25.04.2017
Tranvåg EJ, Onarheim KH
Inkonsekvent om hemmelighold, debattinnlegg i Dagens Medisin 16.03.2017
Onarheim KH, Tranvåg EJ
Udemokratisk hemmelighold, kronikk i NRK Ytring 27.01.2017
Protoner, politikk og prioriteringer, kronikk i Dagens Medisin 26.08.2016
Debatten om kreftmedisiner krever korrekte fakta, debattinnlegg i Aftenposten 19.08.2017
Helsestasjonisme og helseprioriteringer, debattinnlegg i Morgenbladet 12.08.2016
Haaskjold Y, Tranvåg EJ
Den brutal arven etter ebola, kronikk in Aftenposten 11.04.2016
Cand.med., Faculty of Medicine and Dentistry,University of Bergen, Norway, 2005 - 2011
The new era of personalized cancer diagnostics and therapy: seeking new roles for age and biomarkers in clinical decision making
This PhD project is uniquely positioned at the intersection between medical ethics, priority setting, and biomedical and clinical cancer research, and will engage into one of modern medicines most controversial and polemic issues: setting priorities for new precision medicines for advanced and incurable cancer. Precision medicines and targeted therapy for cancer have showed great promise, but have also created new challenges for priority setting in health. Two important personal characteristics are patient age and expression of potential biomarkers, and to utilize such features when tailoring treatment for individual patients can increase benefit and reduce side effects.
However, little is known about how clinical decision-makers actually perceive and use such individual patient characteristics when allocating new and expensive cancer drugs. Our project seeks to fill this gap and the potential benefit is large: At a clinical level, proper use of age and biomarkers in the decision making process will help tailor treatment for each individual patient and it will also assist physicians in their daily clinical work. At an administrative level, our findings will guide and inform the priority setting process at hospitals and among health authorities. At a national level, the work in this project will link naturally up to some of the Norwegian health systems biggest challenges and public debates.